The Src Family of Protein Tyrosine Kinases: A New and Promising Target for Colorectal Cancer Therapy

Jemal, 2008, CA Cancer J Clin, 58, 71, 10.3322/CA.2007.0010

Kopetz, 2009, Improved survival in metastatic colorectal cancer is associated with adoption of hepatic resection and improved chemotherapy, J Clin Oncol, 27, 3677, 10.1200/JCO.2008.20.5278

Taylor, 1996, Src and the control of cell division, Bioessays, 18, 9, 10.1002/bies.950180105

Frame, 2004, Newest findings on the oldest oncogene; how activated src does it, J Cell Sci, 117, 989, 10.1242/jcs.01111

Sicheri, 1997, Structures of Src-family tyrosine kinases, Curr Opin Struct Biol, 7, 777, 10.1016/S0959-440X(97)80146-7

Yeatman, 2004, A renaissance for SRC, Nat Rev Cancer, 4, 470, 10.1038/nrc1366

Martin, 1970, Rous sarcoma virus: a function required for the maintenance of the transformed state, Nature, 227, 1021, 10.1038/2271021a0

Stehelin, 1976, DNA related to the transforming gene(s) of avian sarcoma viruses is present in normal avian DNA, Nature, 260, 170, 10.1038/260170a0

Xu, 2005, Epidermal growth factor receptor (EGFR)-related protein inhibits multiple members of the EGFR family in colon and breast cancer cells, Mol Cancer Ther, 4, 435, 10.1158/1535-7163.MCT-04-0280

Kopetz, 2007, Targeting Src and epidermal growth factor receptor in colorectal cancer: rationale and progress into the clinic, Gastrointest Cancer Res, 1, S37

Kunte, 2005, Down-regulation of the tumor suppressor gene C-terminal Src kinase: an early event during premalignant colonic epithelial hyperproliferation, FEBS Lett, 579, 3497, 10.1016/j.febslet.2005.05.030

Roskoski, 2005, Src kinase regulation by phosphorylation and dephosphorylation, Biochem Biophys Res Commun, 331, 1, 10.1016/j.bbrc.2005.03.012

Summy, 2003, Src family kinases in tumor progression and metastasis, Cancer Metastasis Rev, 22, 337, 10.1023/A:1023772912750

Dehm, 2004, SRC gene expression in human cancer: the role of transcriptional activation, Biochem Cell Biol, 82, 263, 10.1139/o03-077

Talamonti, 1993, Increase in activity and level of pp60c-src in progressive stages of human colorectal cancer, J Clin Invest, 91, 53, 10.1172/JCI116200

Shah, 2007, Src, chemoresistance and epithelial to mesenchymal transition: are they related?, Anticancer Drugs, 18, 371, 10.1097/CAD.0b013e32801265d7

Irby, 1999, Activating SRC mutation in a subset of advanced human colon cancers, Nat Genet, 21, 187, 10.1038/5971

Cam, 2001, Reduced C-terminal Src kinase activity is correlated inversely with pp60 activity in colorectal carcinoma, Cancer, 92, 61, 10.1002/1097-0142(20010701)92:1<61::AID-CNCR1292>3.0.CO;2-D

Hurwitz, 2004, Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer, N Engl J Med, 350, 2335, 10.1056/NEJMoa032691

Bolen, 1987, Activation of pp60c-src protein kinase activity in human colon carcinoma, Proc Natl Acad Sci USA, 84, 2251, 10.1073/pnas.84.8.2251

Termuhlen, 1993, Site-specific differences in pp60c-src activity in human colorectal metastases, J Surg Res, 54, 293, 10.1006/jsre.1993.1046

Cartwright, 1989, pp60c-src activation in human colon carcinoma, J Clin Invest, 83, 2025, 10.1172/JCI114113

Aligayer, 2002, Activation of Src kinase in primary colorectal carcinoma: an indicator of poor clinical prognosis, Cancer, 94, 344, 10.1002/cncr.10221

Jones, 2002, Elevated c-Src is linked to altered cell-matrix adhesion rather than proliferation in KM12C human colorectal cancer cells, Br J Cancer, 87, 1128, 10.1038/sj.bjc.6600594

Brunton, 1997, A role for epidermal growth factor receptor, c-Src and focal adhesion kinase in an in vitro model for the progression of colon cancer, Oncogene, 14, 283, 10.1038/sj.onc.1200827

Irby, 1997, Overexpression of normal c-Src in poorly metastatic human colon cancer cells enhances primary tumor growth but not metastatic potential, Cell Growth Differ, 8, 1287

Lesslie, 2006, Vascular endothelial growth factor receptor-1 mediates migration of human colorectal carcinoma cells by activation of Src family kinases, Br J Cancer, 94, 1710, 10.1038/sj.bjc.6603143

Schlessinger, 2000, New roles for Src kinases in control of cell survival and angiogenesis, Cell, 100, 293, 10.1016/S0092-8674(00)80664-9

Trevino, 2005, Expression and activity of Src regulate interleukin-8 expression in pancreatic adenocarcinoma cells: implications for angiogenesis, Cancer Res, 65, 7214, 10.1158/0008-5472.CAN-04-3858

Kijima, 2002, STAT3 activation abrogates growth factor dependence and contributes to head and neck squamous cell carcinoma tumor growth in vivo, Cell Growth Differ, 13, 355

Yu, 1995, Enhanced DNA-binding activity of a Stat3-related protein in cells transformed by the Src oncoprotein, Science, 269, 81, 10.1126/science.7541555

Bromberg, 1998, Stat3 activation is required for cellular transformation by v-src, Mol Cell Biol, 18, 2553, 10.1128/MCB.18.5.2553

Sen, 2009, Sustained Src inhibition results in signal transducer and activator of transcription 3 (STAT3) activation and cancer cell survival via altered Janus-activated kinase-STAT3 binding, Cancer Res, 69, 1958, 10.1158/0008-5472.CAN-08-2944

Kopetz, 2007, Src continues aging: current and future clinical directions, Clin Cancer Res, 13, 7232, 10.1158/1078-0432.CCR-07-1902

Talpaz, 2006, Dasatinib in imatinib-resistant Philadelphia chromosome-positive leukemias, N Engl J Med, 354, 2531, 10.1056/NEJMoa055229

Green T, Fennell M, Whittaker R, et al. Preclinical activity of AZD0530, a novel, oral, potent, and selective inhibitor of the Src family kinases. Paper presented at: the 2004 EORTC-NCI-AACR Symposium on Molecular Targets and Cancer Therapeutics; September 28-October 1, 2004; Geneva, Switzerland. Poster 361.

Cooper, 2006, A phase I study examining weekly dosing and pharmacokinetics (PK) of a novel spectrum selective kinase inhibitor, XL999, in patients with advanced solid malignancies (ASM), J Clin Oncol, 24, 603s

Coluccia, 2006, SKI-606 decreases growth and motility of colorectal cancer cells by preventing pp60(c-Src)-dependent tyrosine phosphorylation of beta-catenin and its nuclear signaling, Cancer Res, 66, 2279, 10.1158/0008-5472.CAN-05-2057

Bu Y, Gao L, Smolinski M. KX01 (KX2-391), a Src-family kinase inhibitor targeting the peptide-binding domain, suppresses oncogenic proliferation in vitro and in vivo. Paper presented at: the 99th AACR Annual Meeting; April 12-16, 2008; San Diego, CA. Abstract 4983.

Smith, 2009, A phase I study of XL228, a potent IGF1R/AURORA/SRC inhibitor, in patients with solid tumors or hematologic malignancies, J Clin Oncol, 27, 149s

Johnson, 2005, Dasatinib (BMS-354825) tyrosine kinase inhibitor suppresses invasion and induces cell cycle arrest and apoptosis of head and neck squamous cell carcinoma and non-small cell lung cancer cells, Clin Cancer Res, 11, 6924, 10.1158/1078-0432.CCR-05-0757

Boyer, 2002, Src kinase contributes to the metastatic spread of carcinoma cells, Oncogene, 21, 2347, 10.1038/sj.onc.1205298

Messersmith, 2009, Efficacy and pharmacodynamic effects of bosutinib (SKI-606), a Src/Abl inhibitor, in freshly generated human pancreas cancer xenografts, Mol Cancer Ther, 8, 1484, 10.1158/1535-7163.MCT-09-0075

Rajeshkumar, 2009, Antitumor effects and biomarkers of activity of AZD0530, a Src inhibitor, in pancreatic cancer, Clin Cancer Res, 15, 4138, 10.1158/1078-0432.CCR-08-3021

Messersmith, 2007, Bosutinib (SKI-606), a dual Src/Abl tyrosine kinase inhibitor: preliminary results from a phase 1 study in patients with advanced malignant solid tumors, J Clin Oncol, 25, 150s

Eng C, Kopetz S, Morris J, et al. Phase II study of the novel oral Src-kinase inhibitor, AZD0530, in previously treated advanced colorectal cancer patients. Paper presented at: the 99th AACR Annual Meeting; April 12-16, 2008; San Diego, CA. Abstract LB-76.

Adjei, 2009, Results of a phase I trial of KX2-391, a novel non-ATP competitive substrate-pocket directed SRC inhibitor, in patients with advanced malignancies, J Clin Oncol, 27, 148s

Tice, 1999, Mechanism of biological synergy between cellular Src and epidermal growth factor receptor, Proc Natl Acad Sci USA, 96, 1415, 10.1073/pnas.96.4.1415

Maa, 1995, Potentiation of epidermal growth factor receptor-mediated oncogenesis by c-Src: implications for the etiology of multiple human cancers, Proc Natl Acad Sci USA, 92, 6981, 10.1073/pnas.92.15.6981

Stover, 1995, Src phosphorylation of the epidermal growth factor receptor at novel sites mediates receptor interaction with Src and P85, J Biol Chem, 270, 15591, 10.1074/jbc.270.26.15591

Biscardi, 1999, c-Src-mediated phosphorylation of the epidermal growth factor receptor on Tyr845 and Tyr1101 is associated with modulation of receptor function, J Biol Chem, 274, 8335, 10.1074/jbc.274.12.8335

Carpenter, 1999, Employment of the epidermal growth factor receptor in growth factor-independent signaling pathways, J Cell Biol, 146, 697, 10.1083/jcb.146.4.697

Edwin, 2006, A historical perspective of the EGF receptor and related systems, Methods Mol Biol, 327, 1

Kloth, 2003, STAT5b, a mediator of synergism between c-Src and the epidermal growth factor receptor, J Biol Chem, 278, 1671, 10.1074/jbc.M207289200

Biscardi, 1998, Characterization of human epidermal growth factor receptor and c-Src interactions in human breast tumor cells, Mol Carcinog, 21, 261, 10.1002/(SICI)1098-2744(199804)21:4<261::AID-MC5>3.0.CO;2-N

Osherov, 1994, Epidermal-growth-factor-dependent activation of the src-family kinases, Eur J Biochem, 225, 1047, 10.1111/j.1432-1033.1994.1047b.x

Benhar, 2002, Cisplatin-induced activation of the EGF receptor, Oncogene, 21, 8723, 10.1038/sj.onc.1205980

Boerner JL, Biscardi JS, Silva CM, et al. The role of EGF and transactivating agonists in EGFR/c-Src synergy. Paper presented at: the 96th Annual AACR Meeting; April 16-20, 2005; Anaheim, CA. Abstract 5238.

Bao, 2003, Src promotes destruction of c-Cbl: Implications for oncogenic synergy between Src and growth factor receptors, Proc Natl Acad Sci USA, 100, 2438, 10.1073/pnas.0437945100

Lu, 2007, Epidermal growth factor receptor (EGFR) ubiquitination as a mechanism of acquired resistance escaping treatment by the anti-EGFR monoclonal antibody cetuximab, Cancer Res, 67, 8240, 10.1158/0008-5472.CAN-07-0589

Lu Y, Li X, Liang K, et al. Epidermal growth factor receptor (EGFR) ubiquitination as a mechanism of acquired resistance to the anti-EGFR monoclonal antibody cetuximab. Paper presented at: the 97th Annual AACR Meeting; April 14-18, 2007; Los Angeles, CA. Abstract 4082.

Wheeler, 2009, Epidermal growth factor receptor cooperates with Src family kinases in acquired resistance to cetuximab, Cancer Biol Ther, 8, 696, 10.4161/cbt.8.8.7903

Kopetz S, Wu J, Davies M, et al. Synergistic activity of Src and EGFR inhibitors in colon cancer. Paper presented at: the 97th Annual AACR Meeting; April 14-18, 2007; Los Angeles, CA. Abstract 4079.

Feinstein, 2009, Phase I and pharmacokinetic (PK) study of dasatinib (D) and cetuximab (C) in patients (pts) with advanced solid malignancies, J Clin Oncol, 27, 156s

Duxbury, 2004, Inhibition of SRC tyrosine kinase impairs inherent and acquired gemcitabine resistance in human pancreatic adenocarcinoma cells, Clin Cancer Res, 10, 2307, 10.1158/1078-0432.CCR-1183-3

Lesslie DP III, Parikh NU, Shah A, et al. Combined activity of dasatinib (BMS-354825) and oxaliplatin in an orthotopic model of metastatic colorectal carcinoma. Paper presented at: the 97th Annual AACR Meeting; April 1-5, 2006; Washington, DC. Abstract 4745.

Duxbury, 2004, siRNA directed against c-Src enhances pancreatic adenocarcinoma cell gemcitabine chemosensitivity, J Am Coll Surg, 198, 953, 10.1016/j.jamcollsurg.2004.01.037

Avizienyte, 2005, The SRC-induced mesenchymal state in late-stage colon cancer cells, Cells Tissues Organs, 179, 73, 10.1159/000084511

George, 2005, SRC tyrosine kinase and multidrug resistance protein-1 inhibitions act independently but cooperatively to restore paclitaxel sensitivity to paclitaxel-resistant ovarian cancer cells, Cancer Res, 65, 10381, 10.1158/0008-5472.CAN-05-1822

Pengetnze, 2003, Src tyrosine kinase promotes survival and resistance to chemotherapeutics in a mouse ovarian cancer cell line, Biochem Biophys Res Commun, 309, 377, 10.1016/j.bbrc.2003.08.012

Wiener, 2003, Activated Src protein tyrosine kinase is overexpressed in late-stage human ovarian cancers, Gynecol Oncol, 88, 73, 10.1006/gyno.2002.6851

Han, 2006, Antiangiogenic and antitumor effects of Src inhibition in ovarian carcinoma, Cancer Res, 66, 8633, 10.1158/0008-5472.CAN-06-1410

Peterson-Roth, 2009, Src-induced cisplatin resistance mediated by cell-to-cell communication, Cancer Res, 69, 3619, 10.1158/0008-5472.CAN-08-0985

Griffiths, 2004, Expression of kinase-defective mutants of c-Src in human metastatic colon cancer cells decreases Bcl-xL and increases oxaliplatin- and Fas-induced apoptosis, J Biol Chem, 279, 46113, 10.1074/jbc.M408550200

Kopetz, 2009, Synergistic activity of the Src family kinase inhibitor dasatinib and oxaliplatin in colon carcinoma cells is mediated by oxidative stress, Cancer Res, 69, 3842, 10.1158/0008-5472.CAN-08-2246

Finn, 2007, Dasatinib, an orally active small molecule inhibitor of both the src and abl kinases, selectively inhibits growth of basal-type/“triple-negative” breast cancer cell lines growing in vitro, Breast Cancer Res Treat, 105, 319, 10.1007/s10549-006-9463-x

Goetz, 2008, Caveolin-1 in tumor progression: the good, the bad and the ugly, Cancer Metastasis Rev, 27, 715, 10.1007/s10555-008-9160-9